Ipsen reports positive clinical trial data from Dysport study

Ipsen has announced clinical trial data demonstrating the safety and efficacy of Dysport in the treatment of a condition associated with cerebral palsy in children.

Results from a phase III trial published in the scientific journal Pediatrics have shown the benefits Dysport can provide in the treatment of dynamic equinus foot deformity, also known as paediatric lower limb spasticity.

Dysport injections were associated with statistically significant improvements in muscle tone, resulting in an improved overall clinical benefit at week four for both of the assessed dosage levels.

In addition, improvements in spasticity levels and attainment of overall treatment goals were also demonstrated in a statistically and clinically significant manner at week four, while both doses were shown to be well-tolerated.

Claude Bertrand, executive vice-president for research and development and chief scientific officer at Ipsen, said: "The study results confirm the therapeutic value of Dysport in this debilitating condition, the most common cause of chronic motor disability in childhood."

Dysport was first registered in the UK for the treatment of blepharospasm and hemifacial spasm. It is now licensed in 82 countries.